Lima MS, Bacaltchuk J, Schmidt U, Treasure J. Antidepressants for anorexia nervosa. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD004365.14. Walsh BT, Kaplan AS, Attia E, Olmsted M, Parides M, Carter JC e cols. Fluoxetine after weight restoration in anorexia nervosa: a randomized controlled trial. JAMA 2006 Jun 14;295(22):2605-12.15. Walsh BT, Sysko R, Parides MK. Early response to desipramine among women with bulimia nervosa. Int J Eat Disord. 2006 Jan;39(1):72-5.16. Strobel M, Warnke A, Roth M, Schulze U. Paroxetine versus clomipramine in female adolescents suffering from anorexia nervosa and depressive episode--a retrospective study on tolerability, reasons for discontinuing the antidepressive treatment and different outcome measurements. Z Kinder Jugendpsychiatr Psychother. 2004 Nov;32(4):279-89.17. Abbate Daga G, Gianotti L, Mondelli V, Quartesan R, Fassino S. The psychopharmacotherapy of anorexia nervosa: clinical, neuroendocrine and metabolic aspects. J Endocrinol Invest. 2004 Nov;27(10):975-81.18. Schule C, Sighart C, Hennig J, Laakmann G. Mirtazapine inhibits salivary cortisol concentrations in anorexia nervosa. Prog Neuropsychopharmacol Biol Psychiatry. 2006 Aug 30;30(6):1015-9. 19. Jaafar NR, Daud TI, Rahman FN, Baharudin A. Mirtazapine for anorexia nervosa with depression. Aust N Z J Psychiatry. 2007 Sep;41(9):768-9. 20. Wang TS, Chou YH, Shiah ISCombined treatment of olanzapine and mirtazapine in anorexia nervosa associated with major depression.. Prog Neuropsychopharmacol Biol Psychiatry. 2006 Mar;30(2):306-9. 21. Beumont P, Hay P, Beumont D, Birmingham L, Derham H, Jordan A. Australian and New Zealand clinical practice guidelines for the treatment of anorexia nervosa. Aust N Z J Psychiatry. 2005 Jul;39(7):639-40.22. Berkman ND, Bulik CM, Brownley KA, Lohr KN, Sedway JA, Rooks A, Gartlehner G.Management of eating disorders. Evid Rep Technol Assess (Full Rep) 2006 Apr;(135):1-166. 23. Wilson GT, Shafran R. Eating disorders guidelines from NICE. Lancet. 2005 Jan 1-7;365(9453):79-81.24. Leombruni P, Amianto F, Delsedime N, Gramaglia C, Abbate-Daga G, Fassino S. Citalopram versus fluoxetine for the treatment of patients with bulimia nervosa: a single-blind randomized controlled trial. Adv Ther. 2006 May-Jun;23(3):481-9425. Leombruni P, Piero A, Brustolin A, Mondelli V, Levi M, Campisi S e cols. A 12 to 24 weeks pilot study of sertraline treatment in obese women binge eaters. Hum Psychopharmacol. 2006 Apr;21(3):181-8.26. Leombruni P, Piero A, Lavagnino L, Brustolin A, Campisi S, Fassino S. A randomized, double-blind trial comparing sertraline and fluoxetine 6-month treatment in obese patients with Binge Eating Disorder Progress in Neuro-Psychopharmacology and Biological Psychiatry 2008 aug 1;32(6):1599-605. 27. Milano W, Petrella C, Sabatino C, Capasso A. Treatment of bulimia nervosa with sertraline: a randomized controlled trial. Adv Ther. 2004 Jul-Aug;21(4):232-7.28. FDA U.S. Food and Drug Administration [homepage]: Meridia (sibutramine hydrochloride): Follow-Up to an Early Communication about an Ongoing Safety Review. [postado em 21 jan. 2010]. Disponivel em: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm198206.htm.29. Fassino S, Daga GA, Boggio S, Garzaro L, Piero A. Use of reboxetine in bulimia nervosa: a pilot study. J Psychopharmacol. 2004 Sep;18(3):423-8.30. Guerdjikova AI, McElroy SL, Kotwal R, Welge JA, Nelson E, Lake K e cols. High-dose escitalopram in the treatment of binge-eating disorder with obesity: a placebo-controlled monotherapy trial. Hum Psychopharmacol. 2008 Jan;23(1):1-11. 31. Devlin MJ, Goldfein JA, Petkova E, Liu L, Walsh BT. Cognitive behavioral therapy and fluoxetine for binge eating disorder: two-year follow-up. Obesity (Silver Spring)